Suppressor of cytokine signaling 1 modulates invasion and metastatic potential of colorectal cancer cells

Molecular Oncology

Volumn 8, Issue 5, 2014, Pages 942-955

  David, Muriel ^a   Naudin, Cécile ^b   Letourneur, Martine ^a   Polrot, Mélanie ^a   Renoir, Jack Michel ^a   Lazar, Vladimir ^a   Dessen, Philippe ^a   Roche, Serge ^b   Bertoglio, Jacques ^a   Pierre, Josiane ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Centre National de la Recherche Scientifique   (France)

Author keywords

Colorectal cancer; Invasion; Metastasis; SOCS1

Indexed keywords

MICRORNA 200; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN; MICRORNA; MICRORNA 141; MICRORNA 192; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 429; UNCLASSIFIED DRUG; CADHERIN; SOCS1 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING; TRANSCRIPTOME;

ADRENAL METASTASIS; AGGRESSIVENESS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CELL INVASION; CELL STRUCTURE; COLON ADENOCARCINOMA; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; UPREGULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; CELL MIGRATION; COLORECTAL CANCER CELL LINE; COLORECTAL CARCINOMA; FEMALE; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; METASTATIC COLORECTAL CANCER; PHASE CONTRAST MICROSCOPY; TUMOR XENOGRAFT; ANIMAL; CELL ADHESION; COLON; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; RECTUM; TUMOR CELL LINE; TUMOR INVASION;

ANIMALIA; MUS MUSCULUS;

ANIMALS; CADHERINS; CELL ADHESION; CELL LINE, TUMOR; COLON; COLORECTAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RECTUM; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSCRIPTOME;

EID: 84903536219     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.03.014     Document Type: Article

References (51)

1. Ahmed D., Eide P.W., Eilertsen I.A., Danielsen S.A., Eknaes M., Hektoen M., Lind G.E., Lothe R.A. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis 2013, 2:e71.
2. Alexander W.S., Starr R., Fenner J.E., Scott C.L., Handman E., Sprigg N.S., Corbin J.E., Cornish A.L., Darwiche R., Owczarek C.M., Kay T.W., Nicola N.A., Hertzog P.J., Metcalf D., Hilton D.J. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999, 98:597-608.
3. Anastasiadis P.Z., Reynolds A.B. The p120 catenin family: complex roles in adhesion, signaling and cancer. J. Cell Sci. 2000, 113(Pt 8):1319-1334.
4. Bracken C.P., Gregory P.A., Kolesnikoff N., Bert A.G., Wang J., Shannon M.F., Goodall G.J. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 2008, 68:7846-7854.
5. Burk U., Schubert J., Wellner U., Schmalhofer O., Vincan E., Spaderna S., Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008, 9:582-589.
6. Cambien B., Karimdjee B.F., Richard-Fiardo P., Bziouech H., Barthel R., Millet M.A., Martini V., Birnbaum D., Scoazec J.Y., Abello J., Al Saati T., Johnson M.G., Sullivan T.J., Medina J.C., Collins T.L., Schmid-Alliana A., Schmid-Antomarchi H. Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br. J. Cancer 2009, 100:1755-1764.
7. Davis M.A., Ireton R.C., Reynolds A.B. A core function for p120-catenin in cadherin turnover. J. Cell Biol. 2003, 163:525-534.
8. de Krijger I., Mekenkamp L.J., Punt C.J., Nagtegaal I.D. MicroRNAs in colorectal cancer metastasis. J. Pathol. 2011, 224:438-447.
9. Dhawan P., Singh A.B., Deane N.G., No Y., Shiou S.R., Schmidt C., Neff J., Washington M.K., Beauchamp R.D. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J. Clin. Invest. 2005, 115:1765-1776.
10. Edme N., Downward J., Thiery J.P., Boyer B. Ras induces NBT-II epithelial cell scattering through the coordinate activities of Rac and MAPK pathways. J. Cell Sci. 2002, 115:2591-2601.
11. Eger A., Aigner K., Sonderegger S., Dampier B., Oehler S., Schreiber M., Berx G., Cano A., Beug H., Foisner R. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 2005, 24:2375-2385.
12. Frantsve J., Schwaller J., Sternberg D.W., Kutok J., Gilliland D.G. Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol. Cell. Biol. 2001, 21:3547-3557.
13. Fujitake S., Hibi K., Okochi O., Kodera Y., Ito K., Akiyama S., Nakao A. Aberrant methylation of SOCS-1 was observed in younger colorectal cancer patients. J. Gastroenterol. 2004, 39:120-124.
14. Hanada T., Kobayashi T., Chinen T., Saeki K., Takaki H., Koga K., Minoda Y., Sanada T., Yoshioka T., Mimata H., Kato S., Yoshimura A. IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J. Exp. Med. 2006, 203:1391-1397.
15. Huang F.J., Steeg P.S., Price J.E., Chiu W.T., Chou P.C., Xie K., Sawaya R., Huang S. Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis. Cancer Res. 2008, 68:9634-9642.
16. Huang R.Y., Wong M.K., Tan T.Z., Kuay K.T., Ng A.H., Chung V.Y., Chu Y.S., Matsumura N., Lai H.C., Lee Y.F., Sim W.J., Chai C., Pietschmann E., Mori S., Low J.J., Choolani M., Thiery J.P. An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death Dis. 2013, 4:e915.
17. Hur K., Toiyama Y., Takahashi M., Balaguer F., Nagasaka T., Koike J., Hemmi H., Koi M., Boland C.R., Goel A. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 2013, 2:1315-1326.
18. Hurteau G.J., Carlson J.A., Spivack S.D., Brock G.J. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res. 2007, 67:7972-7976.
19. Ilangumaran S., Rottapel R. Regulation of cytokine receptor signaling by SOCS1. Immunol. Rev. 2003, 192:196-211.
20. Ireton R.C., Davis M.A., van Hengel J., Mariner D.J., Barnes K., Thoreson M.A., Anastasiadis P.Z., Matrisian L., Bundy L.M., Sealy L., Gilbert B., van Roy F., Reynolds A.B. A novel role for p120 catenin in E-cadherin function. J. Cell Biol. 2002, 159:465-476.
21. Jackstadt R., Röh S., Neumann J., Jung P., Hoffmann R., Horst D., Berens C., Bornkamm G.W., Kirchner T., Menssen A., Hermeking H. AP4 is a mediator of epithelial-mesenchymal transition and metastasis in colorectal cancer. J. Exp. Med. 2013, 210:1331-1350.
22. Jegalian A.G., Wu H. Regulation of Socs gene expression by the proto-oncoprotein GFI-1B: two routes for STAT5 target gene induction by erythropoietin. J. Biol. Chem. 2002, 277:2345-2352.
23. Kamura T., Maenaka K., Kotoshiba S., Matsumoto M., Kohda D., Conaway R.C., Conaway J.W., Nakayama K.I. VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev. 2004, 18:3055-3065.
24. Leibovitz A., Stinson J.C., McCombs W.B., McCoy C.E., Mazur K.C., Mabry N.D. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 1976, 36:4562-4569.
25. Letourneur M., Valentino L., Travagli-Gross J., Bertoglio J., Pierre J. Sp2 regulates interferon-gamma-mediated socs1 gene expression. Mol. Immunol. 2009, 46:2151-2160.
26. Li Z., Metze D., Nashan D., Muller-Tidow C., Serve H.L., Poremba C., Luger T.A., Bohm M. Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J. Invest. Dermatol. 2004, 123:737-745.
27. Lin S.Y., Yeh K.T., Chen W.T., Chen H.C., Chen S.T., Chiou H.Y., Chang J.G. Promoter CpG methylation of tumor suppressor genes in colorectal cancer and its relationship to clinical features. Oncol. Rep. 2004, 11:341-348.
28. Loboda A., Nebozhyn M.V., Watters J.W., Buser C.A., Shaw P.M., Huang P.S., Van't Veer L., Tollenaar R.A., Jackson D.B., Agrawal D., Dai H., Yeatman T.J. EMT is the dominant program in human colon cancer. BMC Med. Genomics 2011, 4:9.
29. Mahrour N., Redwine W.B., Florens L., Swanson S.K., Martin-Brown S., Bradford W.D., Staehling-Hampton K., Washburn M.P., Conaway R.C., Conaway J.W. Characterization of Cullin-box sequences that direct recruitment of Cul2-Rbx1 and Cul5-Rbx2 modules to Elongin BC-based ubiquitin ligases. J. Biol. Chem. 2008, 283:8005-8013.
30. Marsaud V., Tchakarska G., Andrieux G., Liu J.M., Dembele D., Jost B., Wdzieczak-Bakala J., Renoir J.M., Sola B. Cyclin K and cyclin D1b are oncogenic in myeloma cells. Mol. Cancer 2010, 9:103-122.
31. Morgenstern J.P., Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 1990, 18:3587-3596.
32. Moriggl R., Gouilleux-Gruart V., Jahne R., Berchtold S., Gartmann C., Liu X., Hennighausen L., Sotiropoulos A., Groner B., Gouilleux F. Deletion of the carboxyl-terminal transactivation domain of MGF-Stat5 results in sustained DNA binding and a dominant negative phenotype. Mol. Cell. Biol. 1996, 16:5691-5700.
33. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272:263-267.
34. Nicholson S.E., Willson T.A., Farley A., Starr R., Zhang J.G., Baca M., Alexander W.S., Metcalf D., Hilton D.J., Nicola N.A. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J. 1999, 18:375-385.
35. Pelaez-Garcia A., Barderas R., Torres S., Hernandez-Varas P., Teixido J., Bonilla F., de Herreros A.G., Casal J.I. FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer. PLoS One 2013, 8:e63695.
36. Seguin L., Liot C., Mzali R., Harada R., Siret A., Nepveu A., Bertoglio J. CUX1 and E2F1 regulate coordinated expression of the mitotic complex genes Ect2, MgcRacGAP, and MKLP1 in S phase. Mol. Cell. Biol. 2009, 29:570-581.
37. Shen L., Toyota M., Kondo Y., Lin E., Zhang L., Guo Y., Hernandez N.S., Chen X., Ahmed S., Konishi K., Hamilton S.R., Issa J.P. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:18654-18659.
38. Sirvent A., Boureux A., Simon V., Leroy C., Roche S. The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells. Oncogene 2007, 26:7313-7323.
39. Slattery M.L., Lundgreen A., Kadlubar S.A., Bondurant K.L., Wolff R.K. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer. Mol. Carcinog. 2013, 52:155-166.
40. Spaderna S., Schmalhofer O., Wahlbuhl M., Dimmler A., Bauer K., Sultan A., Hlubek F., Jung A., Strand D., Eger A., Kirchner T., Behrens J., Brabletz T. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res. 2008, 68:537-544.
41. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:15545-15550.
42. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
43. Travagli J., Letourneur M., Bertoglio J., Pierre J. STAT6 and Ets-1 form a stable complex that modulates SOCS-1 expression by IL-4 in keratinocytes. J. Biol. Chem. 2004, 279:35182-35192.
44. Valentino L., Pierre J. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem. Pharmacol. 2006, 71:713-721.
45. Voulgari A., Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim. Biophys. Acta 2009, 1796:75-90.
46. Weisenberger D.J., Siegmund K.D., Campan M., Young J., Long T.I., Faasse M.A., Kang G.H., Widschwendter M., Weener D., Buchanan D., Koh H., Simms L., Barker M., Leggett B., Levine J., Kim M., French A.J., Thibodeau S.N., Jass J., Haile R., Laird P.W. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 2006, 38:787-793.
47. Yang I., Chang O., Lu Q., Kim K. Delta-catenin affects the localization and stability of p120-catenin by competitively interacting with E-cadherin. Mol. Cell 2010, 29:233-237.
48. Yasukawa H., Misawa H., Sakamoto H., Masuhara M., Sasaki A., Wakioka T., Ohtsuka S., Imaizumi T., Matsuda T., Ihle J.N., Yoshimura A. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 1999, 18:1309-1320.
49. Yoshida T., Ogata H., Kamio M., Joo A., Shiraishi H., Tokunaga Y., Sata M., Nagai H., Yoshimura A. SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. J. Exp. Med. 2004, 199:1701-1707.
50. Yoshikawa H., Matsubara K., Qian G.S., Jackson P., Groopman J.D., Manning J.E., Harris C.C., Herman J.G. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet. 2001, 28:29-35.
51. Zhang J.G., Farley A., Nicholson S.E., Willson T.A., Zugaro L.M., Simpson R.J., Moritz R.L., Cary D., Richardson R., Hausmann G., Kile B.J., Kent S.B., Alexander W.S., Metcalf D., Hilton D.J., Nicola N.A., Baca M. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:2071-2076.